Anders Bjartell
51 – 60 of 361
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Re : Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Establishing metastatic prostate cancer quality indicators using a modified Delphi approach
(
- Contribution to journal › Article
-
Mark
Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naïve prostate cancer
(
- Contribution to journal › Article
-
Mark
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
(
- Contribution to journal › Article
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
-
Mark
Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re : Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60
(
- Contribution to journal › Letter
-
Mark
Increasing rates of urinary- and bloodstream infections following transrectal prostate biopsy in South Sweden
(
- Contribution to journal › Article
-
Mark
Detection of lymph node metastases in patients with prostate cancer : Comparing conventional and digital [18F]-fluorocholine PET-CT using histopathology as a reference
(
- Contribution to journal › Article
-
Mark
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme
(
- Contribution to journal › Article